By Fineline Cube cAMPfield Therapeutics, Inc. announced its official launch alongside the completion of a $180 million Series A financing round, establishing the company as a new player in inflammatory disease therapeutics with lead asset prifemilast (HY1999/HPP737), a once-daily oral PDE4 inhibitor for inflammatory bowel disease (IBD) treatment.
Financing Structure & Investor Consortium
| Component | Detail |
|---|---|
| Company Status | Newly launched biotechnology company |
| Financing Round | Series A |
| Amount Raised | USD 180 million |
| Lead Investor | Frazier Life Sciences |
| Participating Investors | Deep Track Capital, Forbion, Abingworth, Venrock, Longitude Capital, Novo Holdings, RA Capital |
| Investor Profile | Premier life sciences investment firms with combined assets under management exceeding $15 billion |
Asset Profile & Development Strategy
- Lead Product: Prifemilast (HY1999/HPP737) – investigational, once-daily oral PDE4B-selective inhibitor
- Indication: Inflammatory bowel disease (IBD) – encompassing Crohn’s disease and ulcerative colitis
- Mechanism Advantage: PDE4B selectivity potentially offers improved safety profile compared to pan-PDE4 inhibitors, which have historically been limited by gastrointestinal side effects
- Development Stage: Advancing toward late-stage clinical development with global rights secured
Corporate Evolution & Rights Transfer
| Transaction Timeline | Parties Involved | Rights Scope |
|---|---|---|
| 2018 | Newsoara Biopharma + vTv Therapeutics | China and Pacific Rim development/commercialization rights |
| February 2026 | Newsoara Biopharma + vTv Therapeutics | Expanded to global rights |
| June 2026 | Newsoara Biopharma → cAMPfield Therapeutics | Global rights transferred to newly formed cAMPfield |
The transaction represents a strategic spin-out of prifemilast into a dedicated company with specialized focus and substantial capital backing, enabling accelerated global development.
Market Opportunity & Competitive Landscape
- IBD Market Size: Global IBD therapeutics market valued at $22 billion in 2025, projected to reach $35 billion by 2030
- Unmet Need: Despite biologic dominance, 30-40% of patients fail to respond adequately or lose response over time, creating demand for novel oral small molecule approaches
- PDE4 Inhibitor Precedent: Otezla (apremilast) demonstrated commercial success in psoriasis/psoriatic arthritis ($2.9 billion annual sales), validating PDE4 inhibition as a viable therapeutic approach
- Competitive Differentiation: Once-daily dosing and PDE4B selectivity may address compliance and tolerability limitations that have hampered previous PDE4 inhibitors in IBD
Strategic Rationale & Investment Thesis
| Stakeholder | Strategic Benefit |
|---|---|
| Investor Consortium | Access to late-stage IBD asset with established safety data and clear regulatory pathway; opportunity to build focused IBD franchise |
| Newsoara Biopharma | Monetizes global asset while retaining potential milestone/royalty participation; focuses resources on core China/Pacific Rim pipeline |
| cAMPfield Therapeutics | Clean corporate structure with dedicated management team; substantial capital runway for pivotal trials and commercial preparation |
Forward‑Looking Statements
This brief contains forward-looking statements regarding cAMPfield Therapeutics’ launch, financing, clinical development plans, and commercial prospects for prifemilast. Actual results may differ due to risks including clinical trial outcomes, regulatory approvals, competitive developments, and market dynamics in the IBD therapeutic landscape.-Fineline Info & Tech